Me

Metsera

New York NYFounded 202230 employees
Private CapbiotechPrivateMetabolic
Platform: Oral Obesity
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
FixafutibatinibMET-3656Preclinical2mAbSMN2PRMT5iIgANNB
GeliglumideMET-1311Phase 12ADCPI3KαPLK4iBCCCF
NidarelsinMET-1497Phase 2/31Fusion ProteinBCL-2DLL3 ADCTTR AmyloidosisOvarian Ca
MET-3015MET-3015Preclinical1mRNAMETC5iMCL
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)
2025-07-15
Geliglumide Interim
Pompe
Past
2026-03-06
Geliglumide AdCom
Pompe
Past
2026-09-15
MET-3015 Interim
MCL
Interim
2026-11-11
Nidarelsin Ph3 Readout
TTR Amyloidosis
Ph3 Readout
2028-10-09
Fixafutibatinib Interim
NB
Interim
2030-09-13
Geliglumide Interim
BCC
Interim